Vitamin D Deficiency, Vitamin D Insufficiency
Conditions
Keywords
Vitamin D, Ultraviolet B radiation
Brief summary
This is a feasibility interventional study seeking to determine the safety and efficacy of the Solius Photobiologic System in increasing the serum levels of 25(OH)D in a vitamin D deficient/insufficient adult population.
Detailed description
The investigators will conduct an interventional study to determine the changes in the changes in serum 25-hydroxyvitamin D levels between subjects who receive weekly exposures to Ultraviolet B Radiation (UVB) generated by the Solius Photobiological System for 4 weeks. Subjects will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 4-week study where they will be exposed to their individualized titration evaluation. Approximately 14 adult participants will be enrolled for serum 25-hydroxyvitamin D screening. The investigators expect to enroll 10 vitamin D-deficient or insufficient subjects in this study. Serum 25-hydroxyvitamin D levels will be measured prior to the first titration (week 2), prior to the intervention (week 6) and after the end of the study, and and the changes in serum 25-hydroxyvitamin D levels will be analyzed. The investigators expect that the levels will increase from the baseline.
Interventions
DEVICEUVB treatment
5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
Sponsors
Boston University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Age at least 22 years old 2. Male or Female 3. Skin Type I-VI 4. Women of childbearing potential must be on birth control and not pregnant based on a negative pregnancy test at baseline. 5. Ability and Willingness to give informed consent and comply to protocol requirements 6. Serum total 25(OH)D \< 30 ng/mL
Exclusion criteria
1. Ongoing treatment with supplemental or pharmacological doses of vitamin D, vitamin D metabolites or analogues 2. Pregnant 3. History of underlying photosensitivity 4. Use of medications that cause a photosensitivity reaction (including but not limited to): tetracycline, tretinoin, amiodarone, doxycycline, naproxen, diphenhydramine, methotrexate, and hydrochlorothiazide 5. History of skin cancer 6. Plan to received significant sun exposure below the 33rd parallel during study 7. Used tanning or phototherapy devices within the last 30 days 8. Vitamin D supplement use of more than 600 IUs daily. 9. Systemic steroids use 10. H1 antihistamine use in the last 7 days 11. Diagnosed with light allergies (including but not limited to): actinic prurigo, polymorphous light eruption, or solar urticaria 12. Diagnosed with light sensitivities (including but not limited to): protoporphyria, photodermatitis, xeroderma pigmentosum, lupus erythematosus, chronic actinic dermatitis, or UV-sensitive syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum 25-hydroxyvitamin D | Serum 25-hydroxyvitamin D at 4 weeks of intervention | Serum 25-hydroxyvitamin D level at 4 weeks of intervention (the end of study) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| UVB Treatment Participants will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined, participants will participate in a 4-week intervention where they will be exposed to their individualized titration evaluation. | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | UVB Treatment |
|---|---|
| Age, Continuous | 28.9 years STANDARD_DEVIATION 7.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment United States | 10 participants |
| Serum 25-hydroxyvitamin D level | 24.0 ng/ml STANDARD_DEVIATION 2.9 |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 10 |
| other Total, other adverse events | 0 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
Serum 25-hydroxyvitamin D
Serum 25-hydroxyvitamin D level at 4 weeks of intervention (the end of study)
Time frame: Serum 25-hydroxyvitamin D at 4 weeks of intervention
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| UVB Treatment | Serum 25-hydroxyvitamin D | 25.4 ng/nl | Standard Deviation 7.3 |